Chemotherapy of vascularised tumours: Role of vessel density and the effect of vascular "pruning"

Journal of Theoretical Biology

Volumn 264, Issue 2, 2010, Pages 253-265

  d'Onofrio, Alberto ^a   Gandolfi, Alberto ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b CNR   (Italy)

Author keywords

Angiogenesis; Chemotherapy; Multistability; Pruning; Tumour

Indexed keywords

BIOLOGICAL DEVELOPMENT; CHEMOTHERAPY; DRUG; GROWTH; NUMERICAL MODEL; TUMOR;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL DENSITY; BLOOD VESSEL PARAMETERS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CHRONOTHERAPY; DRUG EFFICACY; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; SIMULATION; STATISTICAL ANALYSIS; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

ALGORITHMS; ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77951652271     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2010.01.023     Document Type: Article

References (45)

1. Afenya E.K. Acute leukemia and chemotherapy: a modeling viewpoint. Math. Biosci. 1996, 138:79-100.
2. Agur Z., Arakelyan L., Daugulis P., Ginosar Y. Hopf point analysis for angiogenesis models. Discr. Cont. Dyn. Syst. B 2004, 4:29-38.
3. Bertuzzi A., d'Onofrio A., Fasano A., Gandolfi A. Regression and regrowth of tumour cords following single-dose anticancer treatment. Bull. Math. Biol. 2003, 65:903-931.
4. Bodnar M., Forys U. Three types of simple DDE's describing tumour growth. J. Biol. Syst. 2007, 15:453-471.
5. Boyle P., d'Onofrio A., Maisonneuve P., Severi G., Robertson C., Tubiana M., Veronesi U. Measuring progress against cancer in Europe: Has the 15% decline targeted for 2000 come about?. Ann. Oncol. 2003, 14:1312-1325.
6. Browder T., Butterfield C.E., Kräling B.M., Shi B., Marshall B., O'Reilly M.S., Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000, 60:1878-1886.
7. Cojocaru L., Agur Z. A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. Math. Biosci. 1992, 109:85-97.
8. d'Onofrio A., Gandolfi A. Tumour eradication by antiangiogenic therapy: analysis and extension of the model by Hahnfeldt et al. (1999). Math. Biosci. 2004, 191:159-184.
9. d'Onofrio A. A general framework for modelling tumour-immune system and immunotherapy: mathematical analysis and medical inferences. Physica D 2005, 208:220-235.
10. d'Onofrio A. Rapidly acting antitumoral antiangiogenic therapies. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 2007, 76:031920.
11. d'Onofrio A., Gandolfi A., Rocca A. The dynamics of tumour-vasculature interaction suggests low-dose, time-dense antiangiogenic schedulings. Cell Prolif. 2009, 42:317-329.
12. d'Onofrio A., Gandolfi A. A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy. Math. Med. Biol. 2009, 26:63-95.
13. d'Onofrio A., Ledzewicz U., Maurer H., Schättler H. On optimal delivery of combination therapy for tumors. Math. Biosci. 2009, 222:13-26.
14. Drixler T.A., Borel Rinkes I.H., Ritchie E.D., van Vroonhoven T.J., Gebbink M.F., Voest E.E. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res. 2000, 60:1761-1765.
15. Ergun A., Camphausen K., Wein L.M. Optimal scheduling of radiotherapy and angiogenic inhibitors. Bull. Math. Biol. 2003, 191:159-184.
16. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 1972, 175:409-416.
17. Folkman J. Tumor angiogenesis: a possible control point in tumor growth. Ann. Intern. Med. 1975, 82:96-100.
18. Forys U., Kheifetz Y., Kogan Y. Critical-point analysis for three-variable cancer angiogenesis model. Math. Biosci. Eng. 2005, 2:511-525.
19. Frame D. New strategies in controlling drug resistance. J. Manag. Care Pharm. 2007, 13:13-17.
20. Goldie J.H. Drug resistance in cancer: a perspective. Cancer Metastasis Rev. 2001, 20:63-68.
21. Goldie J.H., Coldman A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 1979, 63:1727-1733.
22. Hahnfeldt P., Panigrahy D., Folkman J., Hlatky L. Tumour development under angiogenic signalling: a dynamic theory of tumour growth, treatment response, and postvascular dormancy. Cancer Res. 1999, 59:4770-4778.
23. Hale J.K., Kocak H. Dynamics and Bifurcations 1991, Springer, New York.
24. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001, 7:987-989.
25. Jain R.K., Munn L.L. Vascular normalization as a rationale for combining chemotherapy with antiangiogenesis agents. Princ. Pract. Oncol. 2007, 21:1-7.
26. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 2004, 4:423-436.
27. Kisker O., Becker C.M., Prox D., Fannon M., D'Amato R., Flynn E., Fogler W.E., Sim B.K., Allred E.N., Pirie-Shepherd S.R., Folkman J. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001, 61:7669-7674.
28. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., Bohlen P., Kerbel R.S. Continuous low-dose therapy with vinblastine and VEGF receptor 2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 2000, 105:1045-1047.
29. Ledzewicz U., Schättler H. Drug resistance in cancer chemotherapy as an optimal control problem. Discr. Cont. Dyn. Syst. Ser. B 2006, 6:129-150.
30. Orlando L., Cardillo A., Rocca A., Balduzzi A., Ghisini R., Peruzzotti G., Goldhirsch A., D'Alessandro C., Cinieri S., Preda L., Colleoni M. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 2006, 17:961-967.
31. Norton L., Simon R. The Norton-Simon hypothesis revisited. Cancer Treat. Rep. 1986, 70:163-169.
32. Panetta J.C. A mathematical model of breast and ovarian cancer treated with paclitaxel. Math. Biosci. 1997, 146:89-113.
33. Panetta J.C., Schaiquevich P., Santana V.M., Stewart C.F. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin. Cancer Res. 2008, 14:318-325.
34. Peckham M., Pinedo H., Veronesi U. Oxford Textbook of Oncology 1995, Oxford University Press, Oxford.
35. Rafii S., Lyden D., Benezra R., Hattori K., Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat. Rev. Cancer 2002, 2:826-835.
36. Ribba B., Marron K., Agur Z., Alarcón T., Maini P.K. A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin's lymphoma: investigation of the current protocol through theoretical modelling results. Bull. Math. Biol. 2005, 67:79-99.
37. Sachs R.K., Hlatky L.R., Hahnfeldt P. Simple ODE models of tumour growth and anti-angiogenic or radiation treatment. Math. Comput. Modelling 2001, 33:1297-1305.
38. Schimke R.T. Gene amplification, drug resistance, and cancer. Cancer Res. 1984, 44:1735-1742.
39. Siemann D.W., Rojani A.M. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54:1512-1517.
40. Simeoni M., Magni P., Cammia C., De Nicolao G., Croci V., Pesenti E., Germani M., Poggesi I., Rocchetti M. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 2004, 64:1094-1101.
41. Skipper H.E. On mathematical modeling of critical variables in cancer treatment (goals: better understanding of the past and better planning in the future). Bull. Math. Biol. 1986, 48:253-278.
42. Swierniak A., Polanski A., Kimmel M. Optimal control problems arising in cell-cycle-specific cancer chemotherapy. Cell Prolif. 1996, 29:117-139.
43. Swierniak A. Comparison of six models of antiangiogenic therapy. Appl. Math. 2009, 36:333-348.
44. Ubezio P., Cameron D. Cell killing and resistance in pre-operative breast cancer chemotherapy. BMC Cancer 2008, 8:201.
45. Wheldon T. Mathematical Models in Cancer Research 1988, Hilger Publishing.